Comparing two drugs, ONC201 and everolimus, for DIPG
Original title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage trial, but the drugs are still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study compares two drugs to see which one holds the tumor back longer.
Who this trial is for. This trial is for people with DIPG, and for people with a brain tumor called ND-DMG. It compares two drugs, ONC201 and everolimus, in two treatment groups.
Where it stands. This trial has not reported results. It is measuring how long people go before the tumor grows again. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If the tumor and the situation fit, a family can ask their care team about this trial. The care team can explain what taking part would involve. They can also say whether it makes sense to look into.
What it doesn't mean: It does not mean ONC201 works better than everolimus. Nobody knows that yet. A trial is a test, not a proven treatment. Being in one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.